Patrizia Serra

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 366 citations · Full text

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Matteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri‐Gonzaga et al. · Journal of Clinical Oncology · 2023 · 91 citations

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris et al. · Annals of Oncology · 2021 · 73 citations

Endocrine Oncology, Breast Oncology, Phase Iii Monaleesa-2 +9

Multidisciplinary Approach to the Treatment of Bone Metastases: Osteo-Oncology Center, a New Organizational Model

Toni Ibrahim, Emanuela Flamini, L. Fabbri et al. · Tumori Journal · 2009 · 54 citations

Multiple Myeloma and Work in Agriculture: Results of a Case-Control Study in Forlì, Italy

Oriana Nanni, Fabio Falcini, Eva Buiatti et al. · Cancer Causes & Control · 1998 · 50 citations